Morpholino

MO1-sh3gl3b

ID

ZDB-MRPHLNO-090521-2

Name

MO1-sh3gl3b

Previous Names

MO1-sh3gl3

Target

sh3gl3b (1)

Sequence

5' - TTAAACCCGGCCACTGACATCCTTC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-sh3gl3b

No data available

Phenotype

Phenotype resulting from MO1-sh3gl3b

Phenotype	Fish	Figures
blood decreased fluid flow, abnormal	zn1Tg + MO1-sh3gl3b	Fig. 6 from Gomez et al., 2009
blood cell accumulation sinus venosus, abnormal	AB + MO1-sh3gl3b	Fig. 1 from Zhao et al., 2013
blood circulation absent, abnormal	AB + MO1-sh3gl3b	Fig. 1 from Zhao et al., 2013
blood circulation disrupted, abnormal	zn1Tg + MO1-sh3gl3b	Fig. 6 from Gomez et al., 2009
dorsal aorta decreased diameter, abnormal	zn1Tg + MO1-sh3gl3b	Fig. 1, Fig. 3 from Zhao et al., 2013 Fig. 6 from Gomez et al., 2009
dorsal aorta blood vessel lumenization decreased process quality, abnormal	zn1Tg + MO1-sh3gl3b	Fig. 1, Fig. 3 from Zhao et al., 2013
posterior cardinal vein increased diameter, abnormal	zn1Tg + MO1-sh3gl3b	Fig. 6 from Gomez et al., 2009

Phenotype of all Fish created by or utilizing MO1-sh3gl3b

Phenotype	Fish	Conditions	Figures
blood circulation absent, abnormal	AB + MO1-sh3gl3b	standard conditions	Fig. 1 from Zhao et al., 2013
blood cell accumulation sinus venosus, abnormal	AB + MO1-sh3gl3b	standard conditions	Fig. 1 from Zhao et al., 2013
dorsal aorta decreased diameter, abnormal	zn1Tg + MO1-sh3gl3b	chemical treatment: wortmannin	Fig. S8 from Zhao et al., 2013
blood decreased fluid flow, abnormal	zn1Tg + MO1-sh3gl3b	standard conditions	Fig. 6 from Gomez et al., 2009
dorsal aorta decreased diameter, abnormal	zn1Tg + MO1-sh3gl3b	chemical treatment: tyrphostin AG 1478	Fig. 4 from Zhao et al., 2013
posterior cardinal vein increased diameter, abnormal	zn1Tg + MO1-sh3gl3b	standard conditions	Fig. 6 from Gomez et al., 2009
dorsal aorta decreased diameter, abnormal	zn1Tg + MO1-sh3gl3b	chemical treatment: LY294002	Fig. 3 from Zhao et al., 2013
dorsal aorta blood vessel lumenization decreased process quality, abnormal	zn1Tg + MO1-sh3gl3b	chemical treatment: wortmannin	Fig. S8 from Zhao et al., 2013
blood circulation disrupted, abnormal	zn1Tg + MO1-sh3gl3b	standard conditions	Fig. 6 from Gomez et al., 2009
dorsal aorta decreased diameter, abnormal	zn1Tg + MO1-sh3gl3b	standard conditions	Fig. 1, Fig. 3 from Zhao et al., 2013 Fig. 6 from Gomez et al., 2009
dorsal aorta blood vessel lumenization decreased process quality, abnormal	zn1Tg + MO1-sh3gl3b	chemical treatment: LY294002	Fig. 3 from Zhao et al., 2013
dorsal aorta blood vessel lumenization decreased process quality, abnormal	zn1Tg + MO1-sh3gl3b	standard conditions	Fig. 1, Fig. 3 from Zhao et al., 2013
dorsal aorta blood vessel lumenization decreased process quality, abnormal	zn1Tg + MO1-sh3gl3b	chemical treatment: tyrphostin AG 1478	Fig. 4 from Zhao et al., 2013
dorsal aorta decreased diameter, abnormal	zn1Tg + MO1-egfra + MO1-sh3gl3b	standard conditions	Fig. S9 from Zhao et al., 2013
dorsal aorta blood vessel lumenization decreased process quality, abnormal	zn1Tg + MO1-egfra + MO1-sh3gl3b	standard conditions	Fig. S9 from Zhao et al., 2013
dorsal aorta decreased diameter, abnormal	zn1Tg + MO1-sh3gl3b + MO1-sh3kbp1	standard conditions	Fig. 2 from Zhao et al., 2013
dorsal aorta blood vessel lumenization decreased process quality, abnormal	zn1Tg + MO1-sh3gl3b + MO1-sh3kbp1	standard conditions	Fig. 2 from Zhao et al., 2013

Citations